NCT00196651View on ClinicalTrials.gov

HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection

PHASE2TerminatedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

August 31, 2000

Study Completion Date

February 29, 2004

Conditions

HIV Infection

Interventions

DRUG

IL-2

BIOLOGICAL

LIPO-6T

BIOLOGICAL

ALVAC VIH 1433

Sponsors

Collaborators (1)

Aventis Pharmaceuticals

All Listed Sponsors

collaborator

Aventis Pharmaceuticals

INDUSTRY

lead

French National Agency for Research on AIDS and Viral Hepatitis

OTHER_GOV

NCT00196651 - HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection | Biotech Hunter | Biotech Hunter